Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 81
Filtrar
2.
Nat Med ; 28(1): 71-80, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-35075289

RESUMO

Patients with Wiskott-Aldrich syndrome (WAS) lacking a human leukocyte antigen-matched donor may benefit from gene therapy through the provision of gene-corrected, autologous hematopoietic stem/progenitor cells. Here, we present comprehensive, long-term follow-up results (median follow-up, 7.6 years) (phase I/II trial no. NCT02333760 ) for eight patients with WAS having undergone phase I/II lentiviral vector-based gene therapy trials (nos. NCT01347346 and NCT01347242 ), with a focus on thrombocytopenia and autoimmunity. Primary outcomes of the long-term study were to establish clinical and biological safety, efficacy and tolerability by evaluating the incidence and type of serious adverse events and clinical status and biological parameters including lentiviral genomic integration sites in different cell subpopulations from 3 years to 15 years after gene therapy. Secondary outcomes included monitoring the need for additional treatment and T cell repertoire diversity. An interim analysis shows that the study meets the primary outcome criteria tested given that the gene-corrected cells engrafted stably, and no serious treatment-associated adverse events occurred. Overall, severe infections and eczema resolved. Autoimmune disorders and bleeding episodes were significantly less frequent, despite only partial correction of the platelet compartment. The results suggest that lentiviral gene therapy provides sustained clinical benefits for patients with WAS.


Assuntos
Terapia Genética/métodos , Vetores Genéticos , Transplante de Células-Tronco Hematopoéticas , Lentivirus/genética , Síndrome de Wiskott-Aldrich/terapia , Adolescente , Adulto , Criança , Pré-Escolar , Ensaios Clínicos Fase I como Assunto , Ensaios Clínicos Fase II como Assunto , Humanos , Lactente , Resultado do Tratamento , Síndrome de Wiskott-Aldrich/genética , Síndrome de Wiskott-Aldrich/imunologia , Adulto Jovem
3.
Sci Rep ; 8(1): 8214, 2018 05 29.
Artigo em Inglês | MEDLINE | ID: mdl-29844458

RESUMO

Genome editing is the introduction of directed modifications in the genome, a process boosted to therapeutic levels by designer nucleases. Building on the experience of ex vivo gene therapy for severe combined immunodeficiencies, it is likely that genome editing of haematopoietic stem/progenitor cells (HSPC) for correction of inherited blood diseases will be an early clinical application. We show molecular evidence of gene correction in a mouse model of primary immunodeficiency. In vitro experiments in DNA-dependent protein kinase catalytic subunit severe combined immunodeficiency (Prkdc scid) fibroblasts using designed zinc finger nucleases (ZFN) and a repair template demonstrated molecular and functional correction of the defect. Following transplantation of ex vivo gene-edited Prkdc scid HSPC, some of the recipient animals carried the expected genomic signature of ZFN-driven gene correction. In some primary and secondary transplant recipients we detected double-positive CD4/CD8 T-cells in thymus and single-positive T-cells in blood, but no other evidence of immune reconstitution. However, the leakiness of this model is a confounding factor for the interpretation of the possible T-cell reconstitution. Our results provide support for the feasibility of rescuing inherited blood disease by ex vivo genome editing followed by transplantation, and highlight some of the challenges.


Assuntos
Edição de Genes , Imunodeficiência Combinada Severa/genética , Animais , Proteína Quinase Ativada por DNA/genética , Modelos Animais de Doenças , Humanos , Camundongos , Camundongos SCID , Proteínas Nucleares/genética
4.
Gene Ther ; 20(10): 963-9, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23719067

RESUMO

Primary immunodeficiencies have played a major role in the development of gene therapy for monogenic diseases of the bone marrow. The last decade has seen convincing evidence of long-term disease correction as a result of ex vivo viral vector-mediated gene transfer into autologous haematopoietic stem cells. The success of these early studies has been balanced by the development of vector-related insertional mutagenic events. More recently the use of alternative vector designs with self-inactivating designs, which have an improved safety profile has led to the initiation of a wave of new studies that are showing early signs of efficacy. The ongoing development of safer vector platforms and gene-correction technologies together with improvements in cell-transduction techniques and optimised conditioning regimes is likely to make gene therapy amenable for a greater number of PIDs. If long-term efficacy and safety are shown, gene therapy will become a standard treatment option for specific forms of PID.


Assuntos
Terapia Genética , Vetores Genéticos , Transplante de Células-Tronco Hematopoéticas , Síndromes de Imunodeficiência/terapia , Imunodeficiência Combinada Severa/terapia , Animais , Ensaios Clínicos como Assunto , Humanos , Lentivirus/genética , Transdução Genética , Transplante Autólogo
5.
Gene Ther ; 19(8): 872-6, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22551777

RESUMO

Patients with X-linked severe combined immunodeficiency (SCID-X1) were successfully cured following gene therapy with a gamma-retroviral vector (gRV) expressing the common gamma chain of the interleukin-2 receptor (IL2RG). However, 5 of 20 patients developed leukemia from activation of cellular proto-oncogenes by viral enhancers in the long-terminal repeats (LTR) of the integrated vector. These events prompted the design of a gRV vector with self-inactivating (SIN) LTRs to enhance vector safety. Herein we report on the production of a clinical-grade SIN IL2RG gRV pseudotyped with the Gibbon Ape Leukemia Virus envelope for a new gene therapy trial for SCID-X1, and highlight variables that were found to be critical for transfection-based large-scale SIN gRV production. Successful clinical production required careful selection of culture medium without pre-added glutamine, reduced exposure of packaging cells to cell-dissociation enzyme, and presence of cations in wash buffer. The clinical vector was high titer; transduced 68-70% normal human CD34(+) cells, as determined by colony-forming unit assays and by xenotransplantation in immunodeficient NOD.CB17-Prkdc(scid)/J (nonobese diabetic/severe combined immunodeficiency (NOD/SCID)) and NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl)/SzJ (NOD/SCID gamma (NSG))) mice; and resulted in the production of T cells in vitro from human SCID-X1 CD34(+) cells. The vector was certified and released for the treatment of SCID-X1 in a multi-center international phase I/II trial.


Assuntos
Vetores Genéticos , Subunidade gama Comum de Receptores de Interleucina/genética , Retroviridae/genética , Doenças por Imunodeficiência Combinada Ligada ao Cromossomo X/terapia , Animais , Técnicas de Transferência de Genes , Humanos , Vírus da Leucemia do Macaco Gibão/genética , Camundongos , Camundongos Endogâmicos NOD , Camundongos SCID , Sequências Repetidas Terminais , Transdução Genética
6.
Clin Transl Oncol ; 14(4): 271-9, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22484634

RESUMO

BACKGROUND: Immunotherapy using autologous dendritic cell (DC) vaccination has not been systematically evaluated in osteosarcoma. We therefore conducted a phase I trial to assess feasibility, safety and tumour-specific immune responses in patients with relapsed disease. PATIENTS AND METHODS: Of 13 recruited patients with relapsed osteosarcoma, 12 received 3 weekly vaccines of autologous DCs matured with autologous tumour lysate and keyhole limpet haemocyanin (KLH), to a maximum of 6 vaccinations. An additional 3 paediatric patients afflicted with other tumour types and with relapsed disease received vaccines generated with identical methodology. Immune responses were assessed using an ELISpot assay for the detection of interferon gamma, whilst interleukin-2 and granzyme B were additionally assessed in cases where interferon-γ responses were induced. RESULTS: In total 61 vaccines, of homogeneous maturation phenotype and viability, were administered with no significant toxicity. Only in 2 out of 12 treated osteosarcoma cases was there an induction of specific T-cell immune response to the tumour, whilst a strong but non-specific immune response was induced in 1 further osteosarcoma patient. Immune response against KLH was induced in only 3 out of 12 osteosarcoma patients. In contrast, three additional non-osteosarcoma patients showed significant T-cell responses to vaccine. CONCLUSION: We have shown the strategy of DC vaccination in relapsed osteosarcoma is safe and feasible. However, significant anti-tumour responses were induced in only 2 out of 12 vaccinated patients with no evidence of clinical benefit. Comparison of results with identically treated control patients suggests that osteosarcoma patients might be relatively insensitive to DC-based vaccine treatments.


Assuntos
Vacinas Anticâncer , Osteossarcoma/imunologia , Osteossarcoma/terapia , Linfócitos T/citologia , Adolescente , Adulto , Células Dendríticas/citologia , Estudos de Viabilidade , Feminino , Granzimas/biossíntese , Hemocianinas/química , Humanos , Imunoterapia/métodos , Interferon gama/biossíntese , Interleucina-2/biossíntese , Masculino , Osteossarcoma/metabolismo , Fenótipo , Recidiva , Resultado do Tratamento
7.
Gene Ther ; 19(3): 246-54, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21753795

RESUMO

The need for γ-retroviral (gRV) vectors with a self-inactivating (SIN) design for clinical application has prompted a shift in methodology of vector manufacturing from the traditional use of stable producer lines to transient transfection-based techniques. Herein, we set out to define and optimize a scalable manufacturing process for the production of gRV vectors using transfection in a closed-system bioreactor in compliance with current good manufacturing practices (cGMP). The process was based on transient transfection of 293T cells on Fibra-Cel disks in the Wave Bioreactor. Cells were harvested from tissue culture flasks and transferred to the bioreactor containing Fibra-Cel in the presence of vector plasmid, packaging plasmids and calcium-phosphate in Dulbecco's modified Eagle's medium and 10% fetal bovine serum. Virus supernatant was harvested at 10-14 h intervals. Using optimized procedures, a total of five ecotropic cGMP-grade gRV vectors were produced (9 liters each) with titers up to 3.6 × 10(7) infectious units per milliliter on 3T3 cells. One GMP preparation of vector-like particles was also produced. These results describe an optimized process for the generation of SIN viral vectors by transfection using a disposable platform that allows for the generation of clinical-grade viral vectors without the need for cleaning validation in a cost-effective manner.


Assuntos
Reatores Biológicos , Gammaretrovirus/genética , Vetores Genéticos/isolamento & purificação , Vetores Genéticos/normas , Transfecção/métodos , Animais , Técnicas de Cultura Celular por Lotes/métodos , Técnicas de Cultura Celular por Lotes/normas , Biotecnologia , Linhagem Celular , Gammaretrovirus/isolamento & purificação , Humanos , Camundongos , Controle de Qualidade
8.
Leukemia ; 25(9): 1471-83, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21617701

RESUMO

Severe combined immunodeficiency (SCID) patients with an inactivating mutation in recombination activation gene 1 (RAG1) lack B and T cells due to the inability to rearrange immunoglobulin (Ig) and T-cell receptor (TCR) genes. Gene therapy is a valid treatment option for RAG-SCID patients, especially for patients lacking a suitable bone marrow donor, but developing such therapy has proven challenging. As a preclinical model for RAG-SCID, we used Rag1-/- mice and lentiviral self-inactivating (SIN) vectors harboring different internal elements to deliver native or codon-optimized human RAG1 sequences. Treatment resulted in the appearance of B and T cells in peripheral blood and developing B and T cells were detected in central lymphoid organs. Serum Ig levels and Ig and TCR Vß gene segment usage was comparable to wild-type (WT) controls, indicating that RAG-mediated rearrangement took place. Remarkably, relatively low frequencies of B cells produced WT levels of serum immunoglobulins. Upon stimulation of the TCR, corrected spleen cells proliferated and produced cytokines. In vivo challenge resulted in production of antigen-specific antibodies. No leukemia development as consequence of insertional mutagenesis was observed. The functional reconstitution of the B- as well as the T-cell compartment provides proof-of-principle for therapeutic RAG1 gene transfer in Rag1-/- mice using lentiviral SIN vectors.


Assuntos
Terapia Genética , Vetores Genéticos/administração & dosagem , Proteínas de Homeodomínio/genética , Proteínas de Homeodomínio/fisiologia , Lentivirus/genética , Imunodeficiência Combinada Severa/genética , Imunodeficiência Combinada Severa/terapia , Animais , Linfócitos B/fisiologia , Western Blotting , Medula Óssea/metabolismo , Medula Óssea/patologia , Transplante de Medula Óssea , Proliferação de Células , Citocinas/metabolismo , Ensaio de Imunoadsorção Enzimática , Citometria de Fluxo , Rearranjo Gênico , Técnicas de Transferência de Genes , Humanos , Imunoglobulina G/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , RNA Mensageiro/genética , Receptores de Antígenos de Linfócitos T/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Baço/citologia , Baço/imunologia , Baço/metabolismo , Linfócitos T/fisiologia , Transgenes/fisiologia
9.
Hum Gene Ther ; 22(3): 263-70, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20887212

RESUMO

The efficacy of gene therapy for the treatment of inherited immunodeficiency has been highlighted in recent clinical trials, although in some cases complicated by insertional mutagenesis and silencing of vector genomes through methylation. To minimize these effects, we have evaluated the use of regulatory elements that confer reliability of gene expression, but also lack potent indiscriminate enhancer activity. The Vav1 proximal promoter is particularly attractive in this regard and may be useful in situations where high-level or complex regulation of gene expression is not necessary. X-linked severe combined immunodeficiency (SCID-X1) is a good candidate for such an approach, particularly as there may be additional disease-related intrinsic risks of leukemogenesis, and where safety is therefore a paramount concern. We have tested whether lentiviral vectors expressing the common cytokine receptor gamma chain under the control of the proximal Vav1 gene promoter are effective for correction of signaling defects and the disease phenotype. Despite low-level gene expression, we observed near-complete restoration of cytokine-mediated STAT5 phosphorylation in a model cell line. Furthermore, at low vector copy number, highly effective T- and B-lymphocyte reconstitution was achieved in vivo in a murine model of SCID-X1, in both primary and secondary graft recipients. This vector configuration deserves further evaluation and consideration for future clinical trials.


Assuntos
Terapia Genética , Subunidade gama Comum de Receptores de Interleucina/genética , Regiões Promotoras Genéticas , Proteínas Proto-Oncogênicas c-vav/genética , Animais , Sequência de Bases , Linhagem Celular Tumoral , Modelos Animais de Doenças , Regulação da Expressão Gênica/genética , Ordem dos Genes , Vetores Genéticos/genética , Células HEK293 , Transplante de Células-Tronco Hematopoéticas , Células-Tronco Hematopoéticas/metabolismo , Humanos , Subunidade gama Comum de Receptores de Interleucina/metabolismo , Interleucina-2/metabolismo , Lentivirus/genética , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Camundongos Knockout , Dados de Sequência Molecular , Transdução de Sinais , Doenças por Imunodeficiência Combinada Ligada ao Cromossomo X/genética , Doenças por Imunodeficiência Combinada Ligada ao Cromossomo X/terapia
10.
J Periodontol ; 81(4): 527-34, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20367096

RESUMO

BACKGROUND: Genetic polymorphisms that influence neutrophil function were proposed as possible risk factors for aggressive periodontitis (AgP). The aim of this study is to test whether a clinical diagnosis and specific genetic variants are associated with neutrophil activity in subjects with AgP and healthy subjects. METHODS: This study describes the results of neutrophil analyses performed in 40 subjects (20 subjects with AgP and 20 healthy control subjects). Neutrophils were extracted from peripheral blood and analyzed in a masked manner for phagocytosis and oxidative burst by flow cytometry in response to Escherichia coli, Aggregatibacter actinomycetemcomitans (previously Actinobacillus actinomycetemcomitans), and Porphyromonas gingivalis. Genomic DNA was extracted and genotyped for the nicotinamide adenine dinucleotide phosphate p22 phagocytic oxidase subunit (p22(phox)) cytochrome b alpha gene (CYBA) C242T, crystallizable gamma fragment (Fcgamma)IIa H/R, and FcgammaIIIb neutrophil antigen (NA)1/NA2 polymorphisms. RESULTS: Analyses in pairs of white subjects (n = 24) revealed that patients with AgP exhibited a higher oxidative burst in response to E. coli (P = 0.002) and P. gingivalis (P = 0.002) compared to healthy control subjects. The p22(phox) CYBA 242 T allele was associated with an oxidative burst in response to the challenge by two strains of A. actinomycetemcomitans (P = 0.018 and P = 0.046). The FcgammaIIa polymorphism was associated with the phagocytic index of E. coli (P = 0.024). CONCLUSION: This study confirms previous reports of a higher oxidative burst associated with AgP and presented preliminary evidence that genetic factors may influence neutrophil function in patients with AgP and healthy individuals.


Assuntos
Periodontite Agressiva/genética , Periodontite Agressiva/imunologia , Neutrófilos/imunologia , Explosão Respiratória/genética , Adulto , Aggregatibacter actinomycetemcomitans/fisiologia , Periodontite Agressiva/sangue , Periodontite Agressiva/microbiologia , Alelos , Análise de Variância , Estudos de Casos e Controles , Distribuição de Qui-Quadrado , Escherichia coli/fisiologia , Feminino , Proteínas Ligadas por GPI , Predisposição Genética para Doença , Humanos , Isoantígenos/genética , Masculino , NADPH Oxidases/genética , Neutrófilos/fisiologia , Fagocitose/genética , Polimorfismo de Nucleotídeo Único , Porphyromonas gingivalis/fisiologia , Receptores de IgG/genética
11.
Gene Ther ; 16(11): 1285-91, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19776764

RESUMO

Haematopoietic stem cell transplantation (HSCT) is now widely used to treat primary immunodeficiencies (PID). For patients with specific disorders (severe combined immunodeficiency (SCID)-X1, adenosine deaminase deficiency (ADA)-SCID, X-chronic granulomatous disease (CGD) and Wiskott-Aldrich Syndrome (WAS)) who lack a suitable human leukocyte antigen (HLA)-matched donor, gene therapy has offered an important alternative treatment option. The success of gene therapy can be attributed, in part, to the selective advantage offered to gene-corrected cells, the avoidance of graft-versus-host disease and to the use of pre-conditioning in patients with chemotherapy to facilitate engraftment of corrected cells. Adverse events have been encountered and this has led to detailed characterization of retroviral vector integration profiles. A new generation of self-inactivating retroviral and lentiviral vectors have been designed to address these safety concerns, and are at an advanced stage of preparation for the next phase of clinical testing.


Assuntos
Terapia Genética/métodos , Síndromes de Imunodeficiência/terapia , Animais , Inativação Gênica , Terapia Genética/tendências , Humanos , Masculino , Mutagênese Insercional , Imunodeficiência Combinada Severa/terapia , Síndrome de Wiskott-Aldrich/terapia
12.
Gene Ther ; 16(5): 605-19, 2009 May.
Artigo em Inglês | MEDLINE | ID: mdl-19262615

RESUMO

The woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) is widely used in retroviral gene transfer vectors. However, this element contains an open-reading frame (ORF) encoding a truncated peptide of the woodchuck hepatitis virus X protein (WHX). Because we are developing a lentiviral vector for the gene therapy of Wiskott-Aldrich syndrome (WAS), we evaluated whether the WPRE was needed in the gene transfer cassette and tested the possibility of replacing it with a mutated derivative. The transcriptional activity of the WPRE was undetectable in the context of the lentiviral vector but the element was capable of translating a polypeptide. This capability was abrogated by mutating the WHX ORF translation start. The WPRE was required to express high levels of the transgene and for that, the native form or mutated derivatives functioned equivalently. The vector using a WAS gene promoter and the mut6 WPRE induced long-term expression of the WAS transgene in vivo, correcting cytoskeletal defects, thymocyte and B-cell numbers and improved the colitis of WAS-null mice. By providing additional evidence of efficacy of this WAS lentiviral vector with improved safety features, our results validate a mutated WPRE, which should be useful in future gene therapy applications.


Assuntos
Terapia Genética/métodos , Vetores Genéticos/genética , Vírus da Hepatite B da Marmota/genética , Transativadores/genética , Síndrome de Wiskott-Aldrich/terapia , Animais , Linhagem Celular , Colite/patologia , Colite/terapia , Regulação da Expressão Gênica , Humanos , Lentivirus/genética , Camundongos , Mutação , Fases de Leitura Aberta/genética , Plasmídeos/genética , Transativadores/biossíntese , Transdução Genética , Transgenes , Síndrome de Wiskott-Aldrich/patologia
13.
Gene Ther ; 16(4): 509-20, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19158847

RESUMO

Non-integrating lentiviral vectors show considerable promise for gene therapy applications as they persist as long-term episomes in non-dividing cells and diminish risks of insertional mutagenesis. In this study, non-integrating lentiviral vectors were evaluated for their use in the adult and fetal central nervous system of rodents. Vectors differentially pseudotyped with vesicular stomatitis virus, rabies and baculoviral envelope proteins allowed targeting of varied cell populations. Efficient gene delivery to discrete areas of the brain and spinal cord was observed following stereotactic administration. Furthermore, after direct in utero administration (E14), sustained and strong expression was observed 4 months into adulthood. Quantification of transduction and viral copy number was comparable when using non-integrating lentivirus and conventional integrating vector. These data support the use of non-integrating lentiviral vectors as an effective alternative to their integrating counterparts in gene therapy applications, and highlight their potential for treatment of inherited and acquired neurological disorders.


Assuntos
Encéfalo/metabolismo , Técnicas de Transferência de Genes , Vetores Genéticos/administração & dosagem , Lentivirus/genética , Animais , Corpo Estriado/metabolismo , Terapias Fetais/métodos , Terapia Genética/métodos , Lentivirus/fisiologia , Camundongos , Ratos , Medula Espinal/metabolismo , Técnicas Estereotáxicas , Transdução Genética , Integração Viral
14.
Gene Ther ; 16(1): 111-8, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18784749

RESUMO

Gene therapy has proven to be of potential value for the correction of inherited hematopoietic disorders. However, the occurrence of severe side effects in some of the clinical trials has questioned the safety of this approach and has hampered the use of long terminal repeat-driven vectors for the treatment of a large number of patients. The development of self-inactivating (SIN) vectors with reduced genotoxicity provides an alternative to the currently used vectors. Our initial attempts to use SIN vectors for the correction of a myeloid disorder, chronic granulomatous disease, failed due to low vector titers and poor transgene expression. The optimization of the transgene cDNA (gp91(phox)) resulted in substantially increased titers and transgene expression. Most notably, transgene optimization significantly improved expression of a second cistron located downstream of gp91(phox). Thus, optimization of the transgene sequence results in higher expression levels and increased therapeutic index allowing the use of low vector copy numbers per transduced cell and weaker internal promoters.


Assuntos
Terapia Genética/métodos , Doença Granulomatosa Crônica/terapia , Células-Tronco Hematopoéticas/metabolismo , Glicoproteínas de Membrana/genética , NADPH Oxidases/genética , Animais , Linhagem Celular Tumoral , Expressão Gênica , Vetores Genéticos/administração & dosagem , Vetores Genéticos/genética , Doença Granulomatosa Crônica/metabolismo , Células-Tronco Hematopoéticas/virologia , Humanos , Separação Imunomagnética , Glicoproteínas de Membrana/metabolismo , Camundongos , Camundongos Knockout , NADPH Oxidase 2 , NADPH Oxidases/metabolismo , Retroviridae/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Superóxidos/análise , Transdução Genética/métodos , Transgenes , Inativação de Vírus
15.
J Microsc ; 231(3): 494-505, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18755005

RESUMO

Podosomes are specialized adhesion sites found in rapidly migrating and invasive cells, most notably in cells from the myeloid lineage that participate in immune surveillance and phagocyte defence mechanisms. In this review, we describe the nature of leukocyte podosomes and the regulation of their turnover during migration by the key regulatory molecules Wiskott-Aldrich syndrome protein and WASP-interacting protein.


Assuntos
Movimento Celular , Proteínas do Citoesqueleto/metabolismo , Peptídeos e Proteínas de Sinalização Intracelular/metabolismo , Leucócitos/fisiologia , Proteína da Síndrome de Wiskott-Aldrich/metabolismo , Leucócitos/diagnóstico por imagem , Modelos Biológicos , Ultrassonografia
16.
Gene Ther ; 15(16): 1167-75, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18432275

RESUMO

Gene transfer for cystic fibrosis (CF) airway disease has been hampered by the lung's innate refractivity to pathogen infection. We hypothesized that early intervention with an integrating gene transfer vector capable of transducing the lung via the lumen may be a successful therapeutic approach. An HIV-based lentiviral vector pseudotyped with the baculovirus gp64 envelope was applied to the fetal, neonatal or adult airways. Fetal intra-amniotic administration resulted in transduction of approximately 14% of airway epithelial cells, including both ciliated and non-ciliated epithelia of the upper, mid and lower airways; there was negligible alveolar or nasal transduction. Following neonatal intra-nasal administration we observed significant transduction of the airway epithelium (approximately 11%), although mainly in the distal lung, and substantial alveolar transduction. This expression was still detectable at 1 year after application. In the adult, the majority of transduction was restricted to the alveoli. In contrast, vesicular stomatitis virus glycoprotein pseudotyped virus transduced only alveoli after adult and neonatal application and no transduction was observed after fetal administration. Repeat administration did not increase transduction levels of the conducting airway epithelia. These data demonstrate that application at early developmental stages in conjunction with an appropriately pseudotyped virus provides efficient, high-level transgene expression in the murine lung. This may provide a modality for treatment for lung disease in CF.


Assuntos
Baculoviridae/genética , Terapia Genética/métodos , Vetores Genéticos/administração & dosagem , HIV/genética , Transdução Genética/métodos , Proteínas do Envelope Viral/genética , Animais , Animais Recém-Nascidos , Fibrose Cística/metabolismo , Fibrose Cística/terapia , Feminino , Expressão Gênica , Vetores Genéticos/genética , Proteínas de Fluorescência Verde/análise , Proteínas de Fluorescência Verde/genética , Imuno-Histoquímica , Luciferases/análise , Luciferases/genética , Pulmão/crescimento & desenvolvimento , Pulmão/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos , Modelos Animais , Tempo , Transgenes
17.
Gene Ther ; 14(20): 1439-47, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17909539

RESUMO

Over the last two decades gene therapy has moved from preclinical to clinical studies for many diseases ranging from single gene disorders such as cystic fibrosis and Duchenne muscular dystrophy, to more complex diseases such as cancer and cardiovascular disorders. Gene therapy for severe combined immunodeficiency (SCID) is the most significant success story to date, but progress in many other areas has been significant. We asked 20 leaders in the field succinctly to summarize and comment on clinical gene therapy research in their respective areas of expertise and these are published in two parts in the Progress and Prospect series.


Assuntos
Ensaios Clínicos como Assunto , Terapia Genética/tendências , Doença das Coronárias/terapia , Fibrose Cística/terapia , Oftalmopatias/terapia , Terapia Genética/métodos , Doença Granulomatosa Crônica/terapia , Humanos , Doenças por Armazenamento dos Lisossomos/terapia , Distrofia Muscular de Duchenne/terapia , Doença de Parkinson/terapia , Doenças Vasculares Periféricas/terapia , Imunodeficiência Combinada Severa/terapia , Deficiência de alfa 1-Antitripsina/terapia
18.
Gene Ther ; 14(23): 1623-31, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17851547

RESUMO

The expression of genes specifically in B cells is of great interest in both experimental immunology as well as in future clinical gene therapy. We have constructed a novel enhanced B cell-specific promoter (Igk-E) consisting of an immunoglobulin kappa (Igk) minimal promoter combined with an intronic enhancer sequence and a 3' enhancer sequence from Ig genes. The Igk-E promoter was cloned into a lentiviral vector and used to control expression of enhanced green fluorescent protein (eGFP). Transduction of murine B-cell lymphoma cell lines and activated primary splenic B cells, with IgK-E-eGFP lentivirus, resulted in expression of eGFP, as analysed by flow cytometry, whereas expression in non-B cells was absent. The specificity of the promoter was further examined by transducing Lin(-) bone marrow with Igk-E-eGFP lentivirus and reconstituting lethally irradiated mice. After 16 weeks flow cytometry of lymphoid tissues revealed eGFP expression by CD19+ cells, but not by CD3+, CD11b+, CD11c+ or Gr-1+ cells. CD19+ cells were comprised of both marginal zone B cells and recirculating follicular B cells. Activated human peripheral mononuclear cells were also transduced with Igk-E-eGFP lentivirus under conditions of selective B-cell activation. The Igk-E promoter was able to drive expression of eGFP only in CD19+ cells, while eGFP was expressed by both spleen focus-forming virus and cytomegalovirus constitutive promoters in CD19+ and CD3+ lymphocytes. These data demonstrate that in these conditions the Igk-E promoter is cell specific and controls efficient expression of a reporter protein in mouse and human B cells in the context of a lentiviral vector.


Assuntos
Linfócitos B/virologia , Terapia Genética/métodos , Vetores Genéticos/administração & dosagem , HIV-1/genética , Imunoglobulinas/genética , Regiões Promotoras Genéticas , Animais , Linhagem Celular , Feminino , Citometria de Fluxo , Expressão Gênica , Engenharia Genética , Vetores Genéticos/genética , Proteínas de Fluorescência Verde/genética , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Transdução Genética/métodos , Transgenes
19.
Clin Exp Immunol ; 149(3): 401-9, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17697196

RESUMO

Common variable immunodeficiency (CVID) is a primary immunodeficiency that typically affects adults and is characterized by abnormalities of quantative and qualitative humoral function that are heterogeneous in their immunological profile and clinical manifestations. The recent identification of four monogenic defects that result in the CVID phenotype also demonstrates that the genetic basis of CVID is highly variable. Mutations in the genes encoding the tumour necrosis factor (TNF) superfamily receptors transmembrane activator and calcium-modulating ligand interactor (TACI) and B cell activation factor of the TNF family receptor (BAFF-R), CD19 and the co-stimulatory molecule inducible co-stimulator molecule (ICOS) all lead to CVID and illustrate the complex interplay required to co-ordinate an effective humoral immune response. The molecular mechanisms leading to the immune defect are still not understood clearly and particularly in the case of TACI, where a number of heterozygous mutations have been found in affected individuals, the molecular pathogenesis of disease requires further elucidation. Together these defects account for perhaps 10-15% of all cases of CVID and it is highly likely that further genetic defects will be identified.


Assuntos
Imunodeficiência de Variável Comum/genética , Antígenos CD19/genética , Antígenos CD19/imunologia , Antígenos de Diferenciação de Linfócitos T/genética , Antígenos de Diferenciação de Linfócitos T/imunologia , Imunodeficiência de Variável Comum/imunologia , Predisposição Genética para Doença , Humanos , Proteína Coestimuladora de Linfócitos T Induzíveis , Proteína Transmembrana Ativadora e Interagente do CAML/deficiência , Proteína Transmembrana Ativadora e Interagente do CAML/genética
20.
Br J Cancer ; 97(2): 210-7, 2007 Jul 16.
Artigo em Inglês | MEDLINE | ID: mdl-17595664

RESUMO

Cytokine-modified tumour cells have been used in clinical trials for immunotherapy of neuroblastoma, but primary tumour cells from surgical biopsies are difficult to culture. Autologous fibroblasts, however, are straightforward to manipulate in culture and easy to transfect using nonviral or viral vectors. Here we have compared the antitumour effect of fibroblasts and tumour cells transfected ex vivo to coexpress interleukin-2 (IL-2) and IL-12 in a syngeneic mouse model of neuroblastoma. Coinjection of cytokine-modified fibroblasts with Neuro-2A tumour cells abolished their in vivo tumorigenicity. Treatment of established tumours with three intratumoral doses of transfected fibroblasts showed a significant therapeutic effect with reduced growth or complete eradication of tumours in 90% of mice, associated with extensive leukocyte infiltration. Splenocytes recovered from vaccinated mice showed enhanced IL-2 production following Neuro-2A coculture, and increased cytotoxicity against Neuro-2A targets compared with controls. Furthermore, 100% of the tumour-free mice exhibited immune memory against tumour cells when rechallenged three months later. The potency of transfected fibroblasts was equivalent to that of tumour cells in all experiments. We conclude that syngeneic fibroblasts cotransfected with IL-2 and IL-12 mediate therapeutic effects against established disease, and are capable of generating immunological memory. Furthermore, as they are easier to recover and manipulate than autologous tumour cells, fibroblasts provide an attractive alternative immunotherapeutic strategy for the treatment of neuroblastoma.


Assuntos
Fibroblastos/transplante , Imunoterapia Adotiva/métodos , Interleucina-12/imunologia , Interleucina-2/imunologia , Neuroblastoma/terapia , Animais , Vacinas Anticâncer/imunologia , Vacinas Anticâncer/uso terapêutico , Feminino , Fibroblastos/imunologia , Humanos , Imunidade Celular , Memória Imunológica , Interleucina-12/genética , Interleucina-2/genética , Linfócitos do Interstício Tumoral/imunologia , Camundongos , Camundongos Endogâmicos , Neuroblastoma/imunologia , Neuroblastoma/patologia , Transfecção , Vacinação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...